JAZZ — Jazz Pharmaceuticals plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1232524 ·
Ireland
Last close
$253.87
Market Cap
$15.93B
52W High
$256.75
52W Low
$198.16
ADV30
788,851
Next earnings
2026-08-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,068,900,000 | 934,800,000 | 336,600,000 | 293,100,000 | 11,859,600,000 | 1,844,300,000 | 7,327,300,000 |
| Dec 2025 | 1,197,926,000 | 1,044,398,000 | 254,535,000 | 203,451,000 | 11,659,340,000 | 1,391,899,000 | 7,340,756,000 |
| Sep 2025 | 1,126,107,000 | 997,227,000 | 100,009,000 | 251,412,000 | 11,356,485,000 | 1,326,070,000 | 7,397,455,000 |
| Jun 2025 | 1,045,712,000 | 929,444,000 | 218,970,000 | -718,470,000 | 10,944,141,000 | 1,189,880,000 | 7,237,782,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,334,173,000
Investing CF
$-1,217,813,000
Financing CF
$-138,380,000
CapEx
$-190,552,000
Dividends Paid
—
Buybacks
$-150,001,000
EPS Diluted TTM
$-0.02
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$939,200,000
Inventory
$437,500,000
Receivables
$836,300,000
ST Investments
$1,030,000,000
EBIT TTM
$-37,603,000
Pretax Income TTM
$-218,848,000
Interest Exp TTM
$181,245,000
Analysts
17
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,438,686,208
EBITDA
$2,008,267,008
Free Cash Flow
$1,335,671,424
Enterprise Value
$18,471,118,848
Total Cash
$2,874,299,904
Total Debt
$5,416,900,096
Shares Out
62,742,820
Trailing EPS
$0.10
Book Value
$72.28
ROE
0.7%
ROA
6.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,267,586,000 | 517,622,000 | -356,148,000 | 11,659,340,000 | 7,340,756,000 | — | 1,355,773,000 |
| Dec 2024 | 4,068,950,000 | 726,630,000 | 560,120,000 | 12,012,257,000 | 7,918,501,000 | — | 1,395,908,000 |
| Dec 2023 | 3,834,204,000 | 597,580,000 | 414,832,000 | 11,393,359,000 | 7,656,362,000 | — | 1,092,007,000 |
| Dec 2022 | 3,659,374,000 | 512,268,000 | -224,060,000 | 10,835,255,000 | 7,749,521,000 | — | 1,271,977,000 |
TTM Snapshot
Revenues TTM
$3,805,876,000
NetIncome TTM
$289,394,000
OpCashFlow TTM
$0
Assets (Latest)
$12,012,257,000
Forward EPS
$25.72
Max Pain — expiry 2026-09-18
max pain strike: $210.00 · spot: $253.87 · call oi: 893 · put oi: 751Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BBIO | BridgeBio Pharma, Inc. | $16.46B | $84.02 | — |
| ASND | Ascendis Pharma A/S | $16.65B | $253.86 | — |
| GNMSF | GENMAB A/S | $16.85B | $274.50 | — |
| GMAB | GENMAB A/S | $17.72B | $28.87 | — |
| VTRS | Viatris Inc | $20.08B | $17.24 | — |
News headlines (Yahoo Finance, 1h cache)
Will Jazz (JAZZ) Beat Estimates Again in Its Next Earnings Report?
2026-07-21 16:10 · Yahoo
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026
2026-07-20 20:15 · Yahoo
Jazz Pharmaceuticals (JAZZ) Stock Still Looks Like A Bargain After A 119% Run
2026-07-18 11:14 · Yahoo
Jazz Pharmaceuticals (JAZZ) Refocuses Its Sleep Franchise, Is The Stock Still Cheap?
2026-07-18 07:11 · Yahoo
Apple upgraded, Brinker initiated: Wall Street's top analyst calls
2026-07-17 13:41 · Yahoo
Axsome's NDA for AXS-12 in Narcolepsy Gets FDA Acceptance
2026-07-16 15:58 · Yahoo
3 Value Stocks with Open Questions
2026-07-16 13:21 · Yahoo
Axsome Begins Phase III Study on Solriamfetol for ADHD in Children
2026-07-08 15:19 · Yahoo
Jazz Pharmaceuticals Investors Eye Ziihera Launch in GEA as Key Driver, UBS Says
2026-07-02 15:24 · Yahoo
Why VERAXA Biotech (VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals
2026-07-01 19:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.